Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucopyranosyl lipid adjuvant
- Development stage
- Unknown
- Lead developer
- Access to Advanced Health Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Glucopyranosyl lipid adjuvant (GLA) is a synthetic, hexaacylated monophosphoryl lipid A (MPL) derivative that acts as a potent agonist of **Toll-like receptor 4 (TLR4)**. Developed primarily as a vaccine adjuvant, GLA is designed to activate the innate immune system, specifically inducing Th1-biased CD4+ T-cell responses and robust humoral immunity. The aqueous formulation, known as **GLA-AF**, is frequently utilized in clinical trials to enhance the immunogenicity of recombinant protein antigens. It is currently being evaluated in Phase 1 clinical trials as an adjuvant for the Na-APR-1 (M74) hookworm vaccine and has been investigated in vaccine candidates for schistosomiasis, HIV, and tuberculosis. The molecule was originally developed by the Infectious Disease Research Institute (IDRI), now known as the Access to Advanced Health Institute (AAHI).
- Other names
- gluco-pyranosylphospho-Lipid Asynthetic monophosphoryl lipid Asynthetic hexaacylated lipid AGLA-AF
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on glucopyranosyl lipid adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucopyranosyl lipid adjuvant.